Clinical Trial

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

Name: CD7 CAR-T Cells in T-cell Lymphoma/Leukemia — clinical trial record (NCT05620680)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target. In this study we aim to test the safety and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.

Trial Details

NCT Number	NCT05620680
Lead Sponsor	Shenzhen University General Hospital
Conditions	T Lymphoblastic Leukemia/Lymphoma
Enrollment	20 participants
Start Date	2022-10-01
Primary Completion	2026-10-31 (estimated)
Study Completion	2028-10-31 (estimated)
Updated on ClinicalTrials.gov	2022-11-17